• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    November 14, 2023 - FDA Roundup: November 14, 2023

    11/14/23 3:26:18 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary
    Get the next $AMZN alert in real time by email
    For Immediate Release:
    November 14, 2023

    Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: 

    • On Monday, the FDA updated the advisory for the Investigation of Elevated Lead Levels in Cinnamon Applesauce Pouches to include an expanded recall from WanaBana LLC to include Weis and Schnucks-brand cinnamon applesauce pouches. As of November 13, 2023, there have been 22 reports of illness potentially linked to recalled product submitted to the FDA. The FDA is continuing to evaluate incoming adverse reports of illnesses. The FDA’s investigation is ongoing to determine the source of lead contamination and whether additional products are linked to illnesses. The FDA will update this advisory as information becomes available.
    • On Monday, the FDA issued a warning letter to Amazon.com, Inc. for the firm’s distribution of “Similasan Pink Eye Relief,” “The Goodbye Company Pink Eye,” “Can-C Eye Drops,” “Optique 1 Eye Drops,” “OcluMed Eye Drops,” “TRP Natural Eyes Floaters Relief” and “Manzanilla Sophia Chamomile Herbal Eye Drops” products. These products are not generally recognized as safe and effective for their claimed uses, including temporary relief of minor eye symptoms such as excessive watery (clear) discharge, sensation of grittiness, redness and burning, or pink eye. Therefore, these products are categorized as “new drugs” under the Federal Food, Drug & Cosmetic Act. Ophthalmic drug products are especially concerning from a public health perspective. Products intended for use in the eyes generally pose a greater risk of harm to users because the route of administration for these products bypasses some of the body’s natural defenses. 

    The FDA encourages consumers and health care professionals to report any adverse reactions to the agency’s MedWatch program.

    • On Thursday, the FDA published a safety advisory about an investigation, in collaboration with the U.S. Centers for Disease Control (CDC) and state partners, into human cases of Salmonella Kiambu infection that are potentially associated with pet food made by Mid America Pet Food. Epidemiological data and advice from the CDC can be found in the CDC pet food safety alert.

    Mid America Pet Food has voluntarily recalled all the pet food brands it manufactured with a best by date before 10/31/2024. This includes Victor, Eagle Mountain, Wayne Feeds and two varieties of Member’s Mark pet foods. These products include both dog and cat foods and were sold nationwide in retail stores and online. A full list of the recalled products can be found in the advisory. The investigation is ongoing, and the FDA will update this advisory as appropriate. 

    • On Thursday, the FDA issued a Letter to Health Care Providers about labeling updates for Becton, Dickinson and Company (BD) surgical mesh products. The FDA is aware of increased use of surgical mesh products in breast surgery. The safety and effectiveness of surgical mesh in breast surgery, including in augmentation or reconstruction, has not been determined by the FDA. There are no surgical mesh products cleared or approved by FDA for use in breast surgery, including in augmentation or reconstruction.
    • On Wednesday, the FDA approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy. View full prescribing information for fruquintinib. 
    • On Wednesday, the FDA authorized for marketing the Owlet Baby Care, Inc.’s Dream Sock, an over-the-counter device to monitor the pulse rate and oxygen saturation measurements for infants one to 18 months of age and between six to 30 pounds. This device is intended for use in a home environment and not intended for use with infants previously diagnosed with cardiovascular or respiratory conditions. The safety and effectiveness of this device for the detection or prevention of SIDS/SUID has not been established.
    • On Tuesday, November 7, the FDA revised the existing indication of pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. This updated indication, which remains approved under accelerated approval regulations, restricts its use to patients whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA-approved test. The FDA also approved the Agilent PD-L1 IHC 22C3 pharmDx as a companion diagnostic device to select patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1). View full prescribing information for Keytruda.
    • On Tuesday, November 7, the FDA issued a warning letter to Nic Nac Naturals, LLC for the marketing of their unauthorized dissolvable nicotine products, which the company describes as “nicotine mints” and resemble a pack of mints. The manufacturer markets these tobacco products in a variety of mint and fruit flavors, all of which come in two nicotine strengths (3 milligrams or 6 milligrams). These products are of particular concern because of their resemblance to popular candies and the potential to cause severe nicotine toxicity or even death if accidentally ingested by young children. 
    • On Tuesday. November 7, the FDA approved the ReCor Medical’s Paradise Ultrasound Renal Denervation System, the first breakthrough designated device intended to treat patients with hypertension in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. The system delivers through a catheter ultrasound energy that heats and disrupts nerves surrounding kidney blood vessels. Reduced activity of these nerves results in blood pressure reduction. Hypertension affects approximately 45% of US adults and is linked to an increased risk of stroke, heart disease, and renal disease. Three clinical trials of the ReCor device showed that treatment with the Paradise System led to reduced blood pressure through 2 months after the procedure.

    Related Information

    Related Information
    • FDA Newsroom

    ###

    Boilerplate

    The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.


    Inquiries

    Media:
    FDA Office of Media Affairs
    888-INFO-FDA
    Consumer:
    888-INFO-FDA

     
    Get the next $AMZN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMZN

    DatePrice TargetRatingAnalyst
    8/1/2025$260.00 → $280.00Overweight
    Cantor Fitzgerald
    8/1/2025$225.00 → $260.00Positive
    Susquehanna
    8/1/2025$230.00 → $265.00Buy
    DA Davidson
    8/1/2025$250.00 → $245.00Outperform
    Oppenheimer
    8/1/2025$262.00 → $260.00Buy
    Stifel
    8/1/2025$250.00 → $255.00Overweight
    Piper Sandler
    8/1/2025$255.00 → $265.00Overweight
    Analyst
    8/1/2025$265.00 → $272.00Buy
    BofA Securities
    More analyst ratings

    $AMZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald reiterated coverage on Amazon with a new price target

    Cantor Fitzgerald reiterated coverage of Amazon with a rating of Overweight and set a new price target of $280.00 from $260.00 previously

    8/1/25 11:06:40 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Susquehanna reiterated coverage on Amazon with a new price target

    Susquehanna reiterated coverage of Amazon with a rating of Positive and set a new price target of $260.00 from $225.00 previously

    8/1/25 11:06:40 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    DA Davidson reiterated coverage on Amazon with a new price target

    DA Davidson reiterated coverage of Amazon with a rating of Buy and set a new price target of $265.00 from $230.00 previously

    8/1/25 11:06:13 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    IMDb Launches New B2B Data Licensing Solutions at the IBC Show 2025, Empowering Companies to Grow their Business with Entertainment Data and Insights

    The IMDb activation at the IBC Show (September 12-15 in Amsterdam) will highlight new licensed entertainment data and exclusive insights from the more than 250 million monthly visitors to IMDb; Learn more at developer.imdb.com IMDb CEO Nikki Santoro will join the "Igniting Innovation: Women Leading the Future of AI, Cloud, and Media" panel and networking reception hosted by AWS on Friday, September 12 IMDb (www.imdb.com), the world's most popular and authoritative source for information on movies, TV shows, and celebrities, will launch new entertainment datasets for companies to license at the IBC Show, September 12-15 in Amsterdam. Companies can learn more about licensing authoritative

    9/3/25 12:00:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amazon Launches Infrastructure Region in New Zealand

    AWS Asia Pacific (New Zealand) Region gives customers more choice to run workloads and securely store their content in New Zealand while serving end users with even lower latency Amazon plans to invest more than NZ$7.5 billion and support an average of more than 1,000 full-time equivalent jobs annually in New Zealand, adding approximately NZ$10.8 billion to New Zealand's GDP Active AWS customers in New Zealand include AMP New Zealand, Kiwibank, Ministry of Transport, New Zealand Post, One New Zealand, TVNZ, University of Auckland, Wellington City Council, Xero, and more Amazon (NASDAQ:AMZN) today announced the launch of the AWS Asia Pacific (New Zealand) Region. The new AWS Region wil

    9/1/25 6:01:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    LPL Financial Expands Use of Amazon Business for Key Business Purchasing Needs

    Advisors at leading U.S. wealth firm LPL Financial now enjoy low prices, vast selection, and a trusted shopping experience from Amazon Business Amazon Business offers LPL Financial a global logistics network with hundreds of thousands of suppliers, streamlining purchasing and providing a flexible supply chain with fast delivery Smart analytics and integrations from Amazon Business help investment professionals buy better, saving time and money Amazon (NASDAQ:AMZN) today announced that LPL Financial has expanded its use of Amazon Business, the company's online business-to-business store, to its financial advisors nationwide for their key business purchasing needs. LPL Financial is a le

    8/28/25 9:00:00 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Worldwide Amazon Stores Herrington Douglas J sold $558,725 worth of shares (2,500 units at $223.49), decreasing direct ownership by 0.48% to 518,007 units (SEC Form 4)

    4 - AMAZON COM INC (0001018724) (Issuer)

    9/4/25 5:39:31 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Executive Chair Bezos Jeffrey P gifted 421,693 shares, decreasing direct ownership by 0.05% to 883,258,188 units (SEC Form 4)

    4 - AMAZON COM INC (0001018724) (Issuer)

    9/2/25 4:52:12 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    President and CEO Jassy Andrew R sold $4,403,259 worth of shares (19,872 units at $221.58) and converted options into 49,680 shares, increasing direct ownership by 1% to 2,178,502 units (SEC Form 4)

    4 - AMAZON COM INC (0001018724) (Issuer)

    8/25/25 5:23:50 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 11, 2025 - FDA Roundup: March 11, 2025

    For Immediate Release: March 11, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:Today, the FDA published a General Correspondence Letter issued to Mid-Link Technology Testing Co., Ltd. The FDA is vigilant in ensuring data submitted to the FDA can be relied upon to assess the effectiveness, safety, or risk of a device. The FDA has noted an incr

    3/13/25 3:14:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    November 14, 2023 - FDA Roundup: November 14, 2023

    For Immediate Release: November 14, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA updated the advisory for the Investigation of Elevated Lead Levels in Cinnamon Applesauce Pouches to include an expanded recall from WanaBana LLC to include Weis and Schnucks-brand cinnamon applesauce pouches. As of November 13, 2023, there

    11/14/23 3:26:18 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    SEC Filings

    View All

    SEC Form N-PX filed by Amazon.com Inc.

    N-PX - AMAZON COM INC (0001018724) (Filer)

    8/27/25 4:22:46 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 13F-HR filed by Amazon.com Inc.

    13F-HR - AMAZON COM INC (0001018724) (Filer)

    8/5/25 4:18:54 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 10-Q filed by Amazon.com Inc.

    10-Q - AMAZON COM INC (0001018724) (Filer)

    7/31/25 6:13:08 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    Financials

    Live finance-specific insights

    View All

    Amazon.com Announces Second Quarter Results

    Amazon.com, Inc. (NASDAQ:AMZN) today announced financial results for its second quarter ended June 30, 2025. Net sales increased 13% to $167.7 billion in the second quarter, compared with $148.0 billion in second quarter 2024. Excluding the $1.5 billion favorable impact from year-over-year changes in foreign exchange rates throughout the quarter, net sales increased 12% compared with second quarter 2024. North America segment sales increased 11% year-over-year to $100.1 billion. International segment sales increased 16% year-over-year to $36.8 billion, or increased 11% excluding changes in foreign exchange rates. AWS segment sales increased 17.5% year-over-year to $30.9 billion.

    7/31/25 4:01:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amazon.com to Webcast Second Quarter 2025 Financial Results Conference Call

    Amazon.com, Inc. (NASDAQ:AMZN) announced today that it will hold a conference call to discuss its second quarter 2025 financial results on Thursday, July 31, 2025, at 2:00 p.m. PT/5:00 p.m. ET. The event will be webcast live, and the audio and associated slides will be available for at least three months thereafter at www.amazon.com/ir. View source version on businesswire.com: https://www.businesswire.com/news/home/20250717192665/en/ Amazon.com Public Relations [email protected] amazon.com/ir

    7/17/25 4:01:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amazon.com Announces First Quarter Results

    Amazon.com, Inc. (NASDAQ:AMZN) today announced financial results for its first quarter ended March 31, 2025. Net sales increased 9% to $155.7 billion in the first quarter, compared with $143.3 billion in first quarter 2024. Excluding the $1.4 billion unfavorable impact from year-over-year changes in foreign exchange rates throughout the quarter, net sales increased 10% compared with first quarter 2024. North America segment sales increased 8% year-over-year to $92.9 billion. International segment sales increased 5% year-over-year to $33.5 billion, or increased 8% excluding changes in foreign exchange rates. AWS segment sales increased 17% year-over-year to $29.3 billion. Operati

    5/1/25 4:01:00 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    $AMZN
    Leadership Updates

    Live Leadership Updates

    View All

    eero Celebrates a Decade of Innovation with All-New Wi-Fi 7 Products

    After launching the powerful eero Max 7 and the tough eero Outdoor 7, eero expands Wi-Fi 7 portfolio with all-new eero 7 and eero Pro 7 eero 7 is the company's most affordable Wi-Fi 7 router, offering multi-gigabit speeds in a compact form factor eero Pro 7 delivers premium Wi-Fi 7 performance for high-bandwidth connectivity needs, offering fast wireless and wired speeds with two 5 GbE ports, and capacity for hundreds of devices Amazon (NASDAQ:AMZN) announced that eero is expanding its Wi-Fi 7 portfolio to include eero 7, delivering multi-gigabit speeds at a more affordable price, and eero Pro 7, offering premium performance for bandwidth-demanding networks. Thanks to the company's TrueM

    2/19/25 11:09:00 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    IMDb Announces Leadership Transition as Company Marks 35th Anniversary

    Founder Col Needham Becomes Executive Chair, Nikki Santoro Named CEO, Positioning IMDb for Next Phase of Innovation and Growth IMDb (www.imdb.com), the world's most popular and authoritative source for information on movies, TV shows, and celebrities, today announced that Founder & Chief Executive Officer Col Needham has transitioned to the role of Founder & Executive Chair. Nikki Santoro, who has served as IMDb Chief Operating Officer since 2021, has been appointed the Chief Executive Officer of IMDb. This marks a significant milestone in the company's 35-year history, with Santoro becoming only the second CEO and the first woman to hold the role. This press release features multimedia.

    1/21/25 10:00:00 AM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Superapp Grab Selects AWS as its Preferred Cloud Provider to Drive Technology Innovation and Growth

    Southeast Asia's leading superapp leverages AWS to enhance operational efficiency across eight countries At AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ:AMZN), and Grab, Southeast Asia's leading superapp (NASDAQ:GRAB), announced that Grab has selected AWS as its preferred cloud provider. With AWS, Grab is pursuing a technology-led strategy to accelerate growth across its mobility, deliveries, and financial services verticals, including its new digibanks, while continuing to improve its operational efficiencies and reduce IT infrastructure costs. Grab relies on the world's leading cloud to serve 41.9 million monthly transacting users1 and over 13 mi

    12/4/24 6:30:00 PM ET
    $AMZN
    $GRAB
    Catalog/Specialty Distribution
    Consumer Discretionary
    Real Estate

    $AMZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Amazon.com Inc.

    SC 13G/A - AMAZON COM INC (0001018724) (Subject)

    11/8/24 4:33:15 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Amazon.com Inc.

    SC 13G/A - AMAZON COM INC (0001018724) (Filed by)

    11/7/24 5:23:12 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form SC 13G/A filed by Amazon.com Inc. (Amendment)

    SC 13G/A - AMAZON COM INC (0001018724) (Subject)

    2/13/24 4:55:57 PM ET
    $AMZN
    Catalog/Specialty Distribution
    Consumer Discretionary